Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 32   

Articles published

ARNA 2.13 +0.01 (0.47%)
price chart
Buy Arena Before European Approval Comes Through
Arena Pharmaceutical (NASDAQ:ARNA), a company operating in the healthcare sector, is involved in developing and commercializing drugs that target 'G-protein coupled receptors'.
A Valuation Model For Arena's Belviq
With Arena Pharmaceuticals' (ARNA) Belviq finally approved, Arena will be transitioning from being a cash-starved biotech into an earnings-generating one.
5 Bio-Pharma Stocks To Buy Right Here
Biotechnology and drug stocks offer some of the best potential for big gains in the market. The flip side of that proverbial coin, of course, is a great deal of risk.
Simple Math Showing Why Synergy Pharmaceuticals Is Undervalued
Buying SGYP today after IRWD approval still makes sense just above $5/share. Retail investors have been pounded when trying to play bank-shots off of competitor FDA approvals in recent months.
Inside Nukotoys' Project to Build a Monster iPad Hit for Kids
It's the first time a company has engineered such a literal crossover between old-fashioned physical toys and the digital world of the iPad.
Can Designers And Developers Save Health Care?
Participants who lost 7% of their body weight through dietary changes and increased physical activity dramatically diminished their chances of developing diabetes, soundly defeating the pharmaceuticals. So how was this life-changing intervention ...
SEC Subpoenas Teva Pharmaceutical in Bribery Probe
Teva, Israel's largest company by revenue, is the latest to come under scrutiny in a three-year-old U.S. government investigation of the pharmaceutical industry's compliance with the Foreign Corrupt Practices Act, a 1977 law that bars companies from ...
Rep. Issa Announces House Oversight Committee Will Sue Eric Holder
Hence Issa's Tweet, which moves this battle from the halls of Congress and the White House into the arena of a Federal Court, where Holder will either be compelled to turn over the documents Issa is demanding, or be let off the hook by a judge.
Cadence Pharmaceuticals' Ofirmev Launch Has Gained Traction: Buy
Cadence Pharmaceuticals (CADX) achieved the goal of every emerging bio-pharmaceutical company when it received US approval for its first product Ofirmev on November 2, 2010; it was then launched on January 17, 2011.
8 Intriguing Small Cap Biotechnology Companies For Your Consideration
Yahoo Finance lists 47 biotechnology companies valued between $100 million and $2 billion. Of these, eight gained more than 3% on Friday, most on no news at all.